NetworkNewsBreaks Archive - Page 2077 of 2179

TuesdayJun 13, 2017 10:04 am

NetworkNewsBreaks – Patriot One Technologies, Inc. (TSX.V: PAT) (OTCQB: PTOTF) Reports Confirmed PATSCAN CMR™ Sales Commitments of $2.7M

Patriot One Technologies, Inc. (TSX.V: PAT) (OTCQB: PTOTF), developer of the award-winning PATSCAN CMR™ concealed weapons detection system, this morning announced that it has recorded $2.7 million in confirmed sales commitment since commencing product marketing just three months ago ahead of the ISC West trade show in Las Vegas. “Our roll-out program initially conceived finalizing our engineering in early spring in order to meet Industry Canada and FCC certification requirements by late summer,” Dinesh Kandanchatha, president and CTO of Patriot One, stated in the news release. “We have informed our supply chain partners of the accelerating demand, and I am…

TuesdayJun 13, 2017 9:32 am

NetworkNewsBreaks – Converde Energy USA, Inc. (XFUL) Enters Securities Purchase Agreement with GPL Ventures LLC; Retains Minivest as Advisor

Converde Energy USA, Inc. (OTC: XFUL) this morning announced its entry into a securities purchase agreement with GPL Ventures LLC (“GPL”) through which GPL will have the option to purchase up to $3 million in XFUL common stock when the company has qualified the necessary number of shares under Regulation A through an offering statement. Per the update, XFUL intends to file the offering statement within the next 30 days. “We are very excited to have this investment agreement in place as a primary funding vehicle for the company,” Brad Domitrovitsch, chairman and CEO of XFUL, stated in the news…

TuesdayJun 13, 2017 9:00 am

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Teams with Pharmaseed to Advance Development of INM-750

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced its entry into an agreement with Pharmaseed Ltd., Israel’s largest GLP-certified pre-clinical contract research organization. Under the terms of this agreement, the Pharmaseed development team will now play a key role in the ongoing development of InMed’s lead compound, INM-750, which is a proprietary, topical cannabinoid product candidate that’s currently being studied as a therapy in epidermolysis bullosa and other potential dermatological and wound-healing applications. “This agreement with Pharmaseed now adds one of Israel's leading formulation development teams to our efforts and represents an important strategic…

MondayJun 12, 2017 12:20 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on June 12, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: GTXI 41.42% – News: Releases preliminary results from ongoing phase 2 clinical trial of enobosarm TROV 41.18% – News: Enters into agreement with AstraZeneca to provide Trovera® urine ctDNA test ORGS 14.64% – News: Presenting at the 2017 Marcum MicroCap Conference on June 16 WCST 13.42% – News: Acquires 51% of NextGen Exchange Group MKRS 12.77% – News: Receives second contract from the U.S. Navy for development of a new upgrade to ADSSS® OPXS…

MondayJun 12, 2017 12:20 pm

NetworkNewsBreaks – SeeThruEquity Updates Coverage on BioSig Technologies, Inc. (BSGM)

SeeThruEquity has issued a company update and price target of $3.53 on shares of BioSig Technologies, Inc. (OTCQB: BSGM). Among other highlights, the SeeThruEquity analyst noted the recent expansion of BioSig’s collaboration agreement with the Mayo Clinic. The expanded technology and clinical development partnership has a 10-year term and includes cash warrants and licensing opportunities as well as joint intellectual property filings. The analyst also noted upcoming catalysts for the company, including BioSig’s plans to submit a 510(k) application for clearance to commercialize the PURE EP™ by the third quarter of 2017, and news that the company aims to up-list…

MondayJun 12, 2017 9:21 am

NetworkNewsBreaks – Nektar Therapeutics (NASDAQ: NKTR) Receives “Buy” Rating at Aegis Capital

Aegis Capital has issued a ‘Buy’ rating and price target of $27 on Nektar Therapeutics (NASDAQ: NKTR), stating that the company’s NKTR-214 has wide applicability and the ability to be combined effectively with multiple modalities such as checkpoint inhibitors, cell therapies, small molecules, or vaccines. The company has many upcoming catalysts, including an expansion of the Bristol-Myers Squibb Opdivo collaboration expected in the third quarter of 2017 and a collaboration with Roche Holding's Tecentriq trial that is expected to initiate by mid-2017. For more information, visit www.nektar.com About Nektar Nektar Therapeutics is a research-based biopharmaceutical company that discovers and develops…

MondayJun 12, 2017 9:19 am

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating on Ocera Therapeutics, Inc. (NASDAQ: OCRX)

Following Ocera Therapeutics, Inc.’s (NASDAQ: OCRX) Key Opinion Leader (KOL) conference call on hepatic encephalopathy and other complications of liver disease, Aegis Capital reiterated its ‘Buy’ rating and price target of $3 on shares of the company’s stock. The analyst noted the importance of OCR-002’s potential to reduce hospital stays by 1.5 days and believes that, combined with the IV formulation, the prospective savings for the hospitals could encourage them to adopt OCR-002 when available. Additionally, the company also recently initiated the dosing phase of its phase 1/2a trial of oral OCR-002 in cirrhosis. The end of phase 2 meeting…

MondayJun 12, 2017 9:17 am

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating on Akebia Therapeutics, Inc. (NASDAQ: AKBA)

Aegis Capital has reiterated a ‘Buy’ rating and issued a price target of $25 on shares of Akebia Therapeutics, Inc. (NASDAQ: AKBA) stock. The news follows the company’s recent report of two patent wins in the EU. The Opposition Division (OD) of the European Patent Office has revoked another FibroGen, Inc. hypoxia-inducible factor (HIF) related patent in Europe. Additionally, Akebia’s challenge to a second HIF-related patent resulted in FibroGen considerably narrowing the claims to only cover an indication for vadadustat that Akebia does not intend to develop. The analyst noted its belief that the company now holds a strong IP position…

MondayJun 12, 2017 8:55 am

NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Becomes Exclusive Licensee of Cannabis-Based Treatment for Alzheimer’s Disease

India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced its entry into a definitive license agreement with the University of South Florida that makes the company the exclusive licensee of the U.S. patent filing entitled ‘THC as a Potential Therapeutic Agent for Alzheimer’s Disease’. If the patent filing is granted and proven, IGC anticipates that it could create a “significant therapeutic pathway” in the Alzheimer’s disease market, which is expected to record direct costs in excess of $450 billion annually in the next 12 years. “Securing this…

FridayJun 09, 2017 2:48 pm

NetworkNewsBreaks – AzurRx BioPharma, Inc. (NASDAQ: AZRX) Raises $5M in Private Placement; Proceeds will Fund Continued Development of Lead Candidate

AzurRx BioPharma (NASDAQ: AZRX) this morning announced the closing of a $5 million private placement that the company says will fund the continuation of its lead development program. “We are very grateful for the continued support of our investors and thrilled that the financing was over-subscribed,” AzurRx president and CEO Thijs Spoor stated in the news release. “This financing allows us to continue the development of our MS1819 program for the treatment of exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis patients. In April, AzurRx said early results of its phase IIa trial of MS1819 indicated a favorable safety…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks